Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients

Pharmacotherapy

Volumn 30, Issue 6, 2010, Pages 554-561

  Alexander, Bryan T ^a   Hladnik, Lindsay M ^a   Augustin, Kristan M ^a   Casabar, Ed ^a   McKinnon, Peggy S ^b   Reichley, Richard M ^b   Ritchie, David J ^a,b   Westervelt, Peter ^b   Dubberke, Erik R ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CMV IVIG; Cytomegalovirus disease; Cytomegalovirus intravenous immune globulin; Hematopoietic stem cell transplantation

Indexed keywords

ANTIVIRUS AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS INTRAVENOUS IMMUNE GLOBULIN; DIPHENHYDRAMINE; FOSCARNET; GANCICLOVIR; HYDROCORTISONE; IMMUNOGLOBULIN; PETHIDINE; PREDNISONE; STEROID; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; ENTERITIS; ERYTHEMA; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INTUBATION; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; ONSET AGE; RETROSPECTIVE STUDY; RISK FACTOR; SYMPTOM; TERTIARY HEALTH CARE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VIREMIA; VIRUS PNEUMONIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; MALE;

EID: 77952946091     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.6.554     Document Type: Article

References (39)

1. Pass RF. Epidemiology and transmission of cytomegalovirus. J Infect Dis 1985;152(2):243-248
2. Mwintshi K, Brennan DC. Prevention and management of cytomegalovirus infection in solid-organ transplantation. Expert Rev Anti Infect Ther 2007;5(2):295-304. (Pubitemid 46681747)
3. CSL Behring AG. CytoGam (cytomegalovirus immune globulin intravenous [human]) package insert. Bern, Switzerland; 2007.
4. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008;22(1):89-97. (Pubitemid 351150008)
5. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000;13(1):83-121. (Pubitemid 30039345)
6. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7(9):2106-2113
7. Anonymous. Cytomegalovirus. Am J Transplant 2004;4(suppl 10):51-58
8. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103(3):368-373
9. Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987;257(22):3082-3087 (Pubitemid 17078920)
10. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol 2000;16(1):25-40. (Pubitemid 30066479)
11. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153(3):478-488 (Pubitemid 16135651)
12. Crumpacker C, Marlowe S, Zhang JL, Abrams S, Watkins P. Treatment of cytomegalovirus pneumonia. Rev Infect Dis 1988;10(suppl 3):S538-46.
13. Ettinger NA, Selby P, Powles R, et al. Cytomegalovirus pneumonia: the use of ganciclovir in marrow transplant recipients. J Antimicrob Chemother 1989;24(1):53-62. (Pubitemid 19215025)
14. Tsinontides AC, Bechtel TP. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation. Ann Pharmacother 1996;30(11):1277-1290 (Pubitemid 26367451)
15. Almyroudis NG, Jakubowski A, Jaffe D, et al. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007;9(4):286-294 (Pubitemid 350059149)
16. Huen A, Ippoliti C, Whimbey E, et al. Cytomegalovirus-immune globulin (CytoGam) prophylaxis for the prevention of cytomegalovirus infection and disease in CMV seropositive allogeneic blood and marrow transplantation recipients. Presented as a poster at the 44th American Society of Hematology annual meeting, Philadelphia, PA, December 6-10, 2002.
17. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109(10):783-788 (Pubitemid 19046045)
18. Verdonck LF, de Gast GC, Dekker AW, de Weger RA, Schuurman HJ, Rozenberg-Arska M. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 1989;4(2):187-189 (Pubitemid 19089748)
19. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or = 10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 2006;37(1):51-56 (Pubitemid 43135315)
20. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11): 1245-1251
21. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004;4:94. (Pubitemid 40180260)
22. Haastrup E, Muller K, Baekgaard H, Heilmann C. Cytomegalovirus infection after allogeneic stem cell transplant in children. Pediatr Transplant 2005;9(6):734-740 (Pubitemid 41680708)
23. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European bone marrow transplant group. Clin Infect Dis 1992;14(4): 831-835
24. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988;46(6):905-907 (Pubitemid 19013240)
25. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109(10):777-782
26. Hagenbeek A, Brummelhuis GJ, Donkers A, et al. Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. J Infect Dis 1987;155(5):897-902. (Pubitemid 17062823)
27. DeRienzo SY, Chiang K-Y, O'Neal WM, et al. Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation. Pharmacotherapy 2000;20(10):1175-1178
28. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34(8):1094-1097 (Pubitemid 34289682)
29. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589-1596
30. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36(1): 296-327.
31. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122(1):262-268 (Pubitemid 34754172)
32. Miner JR, Heegaard W, Mapes A, Biros M. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001;21(4):387-392 (Pubitemid 33122102)
33. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998;21(6):597-605. (Pubitemid 28138259)
34. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91(1):78-83. (Pubitemid 43235389)
35. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104(4):961-968 (Pubitemid 39038014)
36. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101(2):407-414 (Pubitemid 36077556)
37. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev 2006;20(1):15-27.
38. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007;40(2):125-136 (Pubitemid 47046210)
39. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy 1995;15(6):765-772